このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MediPal Holdings マネジメント

マネジメント基準チェック /24

MediPal Holdings'の CEO はShuichi Watanabeで、 Apr2012年に任命され、の在任期間は 12.17年です。は、会社の株式の0.083%を直接所有しており、その価値は€ 2.40M 。経営陣と取締役会の平均在任期間はそれぞれ11.8年と7.4年です。

主要情報

Shuichi Watanabe

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	12.3yrs
CEOの所有権	0.08%
経営陣の平均在職期間	11.9yrs
取締役会の平均在任期間	7.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Shuichi Watanabe (72 yo)

12.3yrs

在職期間

Mr. Shuichi Watanabe has been Chief Compliance Officer of MediPal Holdings Corporation since June 25, 2020. Mr. Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Shuichi Watanabe	Chief Compliance Officer	12.3yrs	データなし	0.084% ¥ 2.6m
Yuji Sakon	MD, GM of Administration Division & Director	11.5yrs	データなし	0.011% ¥ 342.7k
Toshihide Yoda	Senior MD of Investor Relations	12.5yrs	データなし	0.0062% ¥ 193.8k
Yasuhiro Choufuku	Executive VP & Director	8.1yrs	データなし	0.025% ¥ 775.2k
Shinjiro Watanabe	GM of Information Systems Management Division & Director	no data	データなし	0.017% ¥ 536.6k

11.9yrs

平均在職期間

70yo

平均年齢

経験豊富な経営陣: 59Zの経営陣は経験豊富で経験豊富です（平均在職期間は11.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Shuichi Watanabe	Chief Compliance Officer	24.5yrs	データなし	0.084% ¥ 2.6m
Yuji Sakon	MD, GM of Administration Division & Director	12.5yrs	データなし	0.011% ¥ 342.7k
Toshihide Yoda	Senior MD of Investor Relations	14.5yrs	データなし	0.0062% ¥ 193.8k
Yasuhiro Choufuku	Executive VP & Director	5.5yrs	データなし	0.025% ¥ 775.2k
Shinjiro Watanabe	GM of Information Systems Management Division & Director	11.5yrs	データなし	0.017% ¥ 536.6k
Yoko Sanuki	Outside Audit & Supervisory Board Member	no data	データなし	データなし
Kuniko Shoji	Independent Outside Director	6.5yrs	データなし	データなし
Toshio Asano	Independent Outside Director	7.5yrs	データなし	0.0034% ¥ 104.4k
Hiroshi Iwamoto	Independent Outside Director	3.5yrs	データなし	データなし
Koichi Mimura	Director	4.5yrs	データなし	0.00096% ¥ 29.9k
Mitsuko Kagami	Independent Outside Director	10.5yrs	データなし	データなし
Seiichi Kasutani	Director	5.5yrs	データなし	データなし

7.5yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: 59Zの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

MediPal Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024

MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).

Full year 2024 earnings released: EPS: JP¥196 (vs JP¥185 in FY 2023)

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: JP¥185 (vs JP¥140 in FY 2022)

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥140 (vs JP¥114 in FY 2021)

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Now 21% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue beats expectations

New 90-day high: €16.92

New 90-day high: €16.80

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

Second quarter 2021 earnings released: EPS JP¥23.93

Revenue misses expectations

First half earnings released

Semi-annual earnings released: Revenue misses expectations

New 90-day low: €15.20

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020

First quarter earnings released

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24